Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda following TACE in primary liver carcinoma
NCT03397654Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jan 2018
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Imperial College London. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03397654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397654.